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Abstract: Conjugates of small molecule drugs with antibodies (ADCs) and with other 
proteins (protein-drug conjugates, PDC) are used as a new class of targeted therapeutics 
combining the specificity of monoclonal antibodies (mAbs) and other proteins with potent 
cytotoxic activity of small molecule drugs for the treatment of cancer and other diseases. 
A(P)DCs have three major components, antibody (targeting protein), linker and payload, 
the cytotoxic drug. Recently, advances in identifying targets, selecting highly specific 
mAbs of preferred isotypes, optimizing linker technology and improving chemical methods 
for conjugation have led to the approval of two ADCs by Food and Drug Administration 
(FDA) and more than 30 ADCs in advanced clinical development. However, the complex 
and heterogeneous nature of A(P)DCs often cause poor solubility, instability, aggregation 
and eventually unwanted toxicity. This article reviews the main components of A(P)DCs, 
and discusses the choices for drugs, linkers and conjugation methods currently used. Future 
work will need to focus on developments and strategies for overcoming such major 
problems associated with the A(P)DCs. 
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1. Introduction 
An ideal anti-tumor drug kills tumor cells efficiently but leaves normal cells intact. With the 
emergence of antibody-drug conjugates (ADCs) we may be a step closer to this goal. Therapeutic 
antibodies have exquisite specificity toward antigens that they are designed to recognize. Conjugated 
with potent cytotoxic drugs, which are otherwise too toxic to use alone, ADCs promise to deliver these 
cytotoxic drugs directly into tumor cells and release the drug inside cells. Approval of Brentuximab 
vedotin (ADCETRIS
®) by US FDA in 2011 has ushered many other similar ADCs into the 
development for cancer therapy [1,2]. Brentuximab vedotin [3] was approved to treat Hodgkin’s 
lymphoma (HL) after failure of autologous stem cell transplantation, and systemic anaplastic large cell 
lymphoma (ALCL) after failure of multi-agent treatment. In February 2013, US FDA approved 
trastuzumab emtansine (Kadcyla™) for patients with HER2-positive, late-stage (metastatic) breast 
cancer [4]. It has been reported that currently more than 30 ADCs are in clinical studies [5].  
This article reviews the main components of ADCs and other protein-drug conjugates (PDCs), and 
discusses choices for drugs and conjugations by using ADCs currently under late clinical studies as 
examples. Several recent reviews provide details in efficacy and adverse effects of these ADCs [1,2,6–10].  
2. Antibodies and Targets 
Therapeutic antibodies eliminate target cells through two mechanisms in general. One is through 
triggering signaling from the receptor, which may lead to apoptosis or disrupting signal transduction 
essential for growth, such as bevacizumab [11]. This mechanism is usually determined by the inherent 
nature of the antibody’s target. Agonistic antibodies, such as PRO95780, targeting the death receptors 
are examples of this mechanism [12]. The other mechanism is through the effector function of 
antibodies, namely antibody-dependent cell-mediated cytotoxicity (ADCC) and complement- dependent 
cytotoxicity (CDC). Immunoglobulin isotypes IgG1 and IgG3, are capable of mediating these effector 
functions [13]. However, in many cases, these cell-killing mechanisms are not sufficient to eliminate 
tumor cells. In addition, some antibodies with high specificity to cancer antigens may lack therapeutic 
effect by themselves. Conjugating these antibodies to potent cytotoxic drugs is an excellent way to 
empower these antibodies.  
An appropriate ADC target should have elevated levels on tumor cells and limited expressions in 
normal cells. For example, Her2 has been shown to overexpress in significant portion of metastatic 
breast cancers, and with very restricted distribution in normal cells [14,15]. Identifying such cancer 
differential targets is one of the most important steps in developing ADCs. Higher density of the target 
molecules could facilitate introduction of more cytotoxic drugs into cells. In addition to selective 
expression in cancer cells, target molecules should undergo internalization mostly through the early 
endosome-lysosome pathway [16]. As the targeting moiety of the ADCs, other than characteristics a 
typical therapeutic antibody should have (e.g., high specificity and high affinity), the antibody 
preferentially triggers the internalization upon its binding to the cell surface receptor, making ADCs Biomedicines 2014, 2 3 
 
 
available to intracellular processing [17]. The internalization of antibody/receptor complex may be 
mediated through the direct engagement of the receptor or clustering of multiple receptors [18,19]. 
Many receptors, such as G protein coupled receptors (GPCRs), have adapted a mechanism to 
desensitize to repeated or prolonged exposure by recycling rapidly back to cytoplasmic membrane 
through early endosomes [20], which makes them less ideal as ADC targets. However, an ADC targeting 
the GPCR family member endothelin receptor type B (ETBR), Anti-ETBR-MC-vc-PAB-MMAE, has 
been advanced to clinical development [21], which suggests that unexplored GPCRs with effective 
internalization could be potential targets for the ADCs [22]. 
A selected list of ADCs in late stage clinical development and their components along with the 
details of targets, cytotoxic drugs, therapeutic area, and status is given in Table 1. 
Table 1. Examples of antibody-drug conjugates in late clinical development (grouped by 
conjugation methods and drug release mechanisms). 
ADC name  Target  Cytotoxic drug  Therapeutic area  Current status 
Linked to cysteines via maleimidocaproyl-VC dipeptide-PAB-MMAE and cleavage by cathepsin B 
Brentuximab vedotin  CD30  MMAE  HL, ALCL 
Approved 
(2011) 
CDX-011 (Glembatumumab vedotin)  GPNMB  MMAE  Breast cancer melanoma  Phase 2 
RG-7593 (Pinatuzuumab vedotin) 
DCDT2980S 
CD22 MMAE 
DLBL, follicular  
non-Hodgkin’s lymphoma 
Phase 2 
PSMA-ADC PSMA  MMAE  Prostate cancer  Phase 2 
Linked to lysines via SMCC thioether and released by proteolytic degradation of antibody 
Trastuzumab emtansine  Her2  Maytansinoid DM1  Metastatic breast cancer 
Approved 
(2013) 
Milatuzumab-dox  CD74  doxorubicin  Multiple myeloma  Phase 2 
Linked to lysines via acetyl butyrate hydrazone and released by hydrolysis at low pH 
Gemtuzumab ozogamicin  CD33 
N-acetyl- γ 
calicheamicin 
AML withdrawn 
Inotuzumab ozogamincin  CD22 
N-acetyl- γ 
calicheamicin 
NHL, ALL  Phase 3 
Linked to lysines via hindered disulfide bond in SPDB and released by reductive cleavage 
BT062  CD138  maytansinoid  Multiple myeloma  Phase 2 
SAR3419  CD19  maytanisinoid  DLBL, ALL  Phase 2 
Lorvotuzumab mertansine  
(IMGN-901) 
CD56 maytanisinoid  Small-cell lung cancer  Phase 2 * 
Abbreviations: MMAE, monomethylauristatin E; VC, valine citrulline; SMCC, 4-(-maleimidomethyl)cyclohexanecarboxylic 
acid N-hydroxysuccinimide ester; SPDB, N-succinimidyl 3-(2-pyridyldithiol)butyrate; SPP, N-succinimidyl   
4-(2-pyridyldithio)pentanoate; HL, Hodgkin lymphoma; ALCL, anaplastic large-cell lymphoma; AML, acute myeloid 
leukemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphocytic leukemia; DLBL, diffuse large B-cell lymphoma; 
GPNMB, glycoprotein nonmetastatic B; PSMA, prostate-specific membrane antigen; * Lorvotuzumab phase 2 studied has 
been discontinued. 
Although the vast majority of reported ADCs employ humanized or fully human antibodies as the 
guiding molecules, other proteins could perform this function. For instance, soluble forms of the HIV-1 
primary receptor CD4 (sCD4) are potentially promising molecules which could target cytotoxic drugs Biomedicines 2014, 2 4 
 
 
to and kill HIV-1-infected cells expressing the viral envelope glycoproteins (Envs) on cell surface [23]. 
Two recent studies showed that decreasing the molecular size of sCD4, which typically is composed of 
either four (D1–4) or two (D1D2) extracellular CD4 domains, to a single domain (D1) and engineering 
D1 through mutagenesis lead to largely reduced nonspecificity (e.g., interactions with the major 
histocompatibility complex class II and presumably other targets) of D1 while preserving D1 binding 
and cross-reactivity with the Envs [24,25]. Therefore, D1 could be superior to D1–4 and D1D2 as a 
component of the targeting molecules. Interestingly, a class of antibodies targeting the HIV-1 
coreceptor-binding site on the Envs (designated as CD4i antibodies) synergize with sCD4 in binding 
and neutralization because their epitopes are better exposed or formed in the presence of sCD4 [26–28]. 
It has been proposed that sCD4–CD4i antibody fusion proteins could be better than sCD4 or the 
antibody alone as targeting molecules of not only ADCs or PDCs but also bispecific antibodies and 
chimeric antigen receptors (CARs) to guide naturally occurring killer cells for HIV-1 eradication [23]. 
3. Cytotoxic Drugs and Mechanisms of Action 
It is critical to maintain the antibody pharmocokinetics, antigen binding ability and thermostability 
of ADCs. There are limited numbers of drug molecules that can be attached to antibody. Too many 
drug molecules lead to short serum half life of ADCs and increased hydrophobicity [29,30]. The current 
consensus is three to four molecules of drug per antibody [1,2]. In the early days of protein-drug 
conjugates, toxins such as ricin were used [31]. The chemotherapy drugs doxorubicin [32,33], 
methotrexate [34], vinca alkaloids [35], etc., have also been conjugated to antibodies. These drugs 
were found not potent enough to kill cancer cells, especially in solid tumors where only suboptimal 
amount of drug are delivered and accumulated. More potent cytotoxic drugs were later used for 
preparing ADCs. Although these potent cell killing drugs are too toxic to use as free drug, they have 
been proven to be safe and potent when conjugated with tumor specific antibodies. The drugs used in 
ADCs currently may be classified into two families: drugs that damage DNA and drugs that disrupt 
microtubule polymerization [36].  
Duocarmycin and calicheamicin are two examples of DNA damaging agents. Duocarmycin was 
first isolated from culture of Streptomyces. It binds to the minor groove of DNA and alkylates the 
nucleobase adenine, which leads to DNA double strand breaks and apoptosis. It has IC50 of ~10 pM 
against cancer cells [37]. Synthetic analogs of duocarmycin are available in modified and pro-drug 
forms for stability requirement before it reaches DNA. MDX-1203, for example, a CD70 targeting 
ADC conjugated with duocarmycin pro-drug which is under development for treating Non-Hodgkin’s 
lymphoma and renal cell carcinoma [38].  
Calicheamicin was first isolated in 1980s from Micromonospora echinospora that live in caliche 
clay. It belongs to the family of enediyne antibiotics. Calicheamicins bind with DNA in the minor 
groove, where they then undergo a reaction analogous to the Bergman cyclization, generating a 
diradical species. The diradical intermediates remove hydrogen atoms from the deoxyribose backbone 
of DNA which results in strand breaks [39]. Calicheamicin is one of the most potent antitumor agents 
known. It impacts both quiescent and proliferating cells. N-acetyl-γ calicheamicin is the cytotoxic 
compound in both Gemtuzumab ozogamicin and Inotuzumab ozogamincin [17]. Gemtuzumab Biomedicines 2014, 2 5 
 
 
ozogamicin was the first ADC approved by US FDA for acute myeloid leukemia and later withdrawn 
for safety concerns [40]. Inotuzumab ozogamincin is currently in phase 3 clinical trial.  
Auristatins and maytansinoids are the two most selective microtubule disrupting drugs for ADCs. 
Both are vinca-domain binders of β-tubulin and prevent polymerization of tubulins into microtubules 
and disrupt mitotic spindles [36,41]. Therefore, their cytotoxicity is mainly on dividing cells. 
Monomethyl auristatin E (MMAE), the payload in Brentuximab vedotin, is a synthetic   
dolastatin 10 derivative. Dolastatin 10 is a lipophilic pentapeptide isolated from the mollusk   
Dolabella auricularia [42]. As an antitumor agent, it is more potent than vinblastine and taxol. Total 
synthesis of dolastatin 10 was reported in 1989 [43]. Dolastatins may be sensitive to the efflux pump 
by the multi-drug resistant p-glycoprotein [36]. Monomethyl auristatin F (MMAF) has a charged   
C-terminal phenylalanine residue instead of a carboxyl residue [44]. In comparison with MMAE, 
MMAF has attenuated membrane translocation capacity, less potent (higher maximal tolerated dose), 
and much higher aqueous solubility. ADCs comprising MMAE include the FDA approved 
Brentuximab vedotin [3], and other ADCs that are in late stage clinical development such as 
Glembatumumab vedotin [45], Pinatuzuumab vedotin [46] and PSMA-ADC [47]. ADCs targeting 
CD30 [44] and CD22 [48] have the MMAF as a payload component which exhibited different 
properties and activities as compared to ADCs anti-CD30-MMAE and CD22-DM1 respectively. 
Maytainsine is a type of ansamycin antibiotics originally isolated from Ethiopian shrub Maytenus 
serrate, which inhibits tubulin polymerization and binding at a rhizoxin binding site. Trastuzumab 
emtansine (T-DM1, Kadcyla
®) targeting the human epidermal growth factor receptor (HER2) which 
was approved by FDA has the DM1 (derivative of maytansine) as potent cytotoxic component of  
the ADC [4]. 
4. Linkers and Conjugation Chemistry 
The potent cytotoxic drugs are covalently attached to antibodies through linkers, and the linker 
stability is critical to the efficacy of ADCs. Stability of ADCs before they reach target cells is the key 
to minimize off-target killing and maximize tumor exposure to drugs. Upon internalization of ADCs 
into cells, linkers should be labile enough to ensure rapid release of drugs into cytoplasm where they 
bind to tubulins or DNA molecules. Design of linker/spacer is intricately related to how ADC will 
exert its cytotoxicity intracellularly. The choice of linker determines the release mechanism of drugs 
that is often limited by chemistry and biology of cancer cells.  
Heterobifunctional linkers are commonly used in ADCs [49], because they allow attachment   
of drugs through disulfide bond and amide bond. A typical example of linker, such as   
4-(-maleimidomethyl)cyclohexanecarboxylic acid N-hydroxysuccinimide ester (SMCC) has   
N-hydroxysuccinimide (NHS) ester, which reacts with primary amines to form amide bond, and 
maleimide group that reacts with sulfhydryl group to form stable thioether bond. Linkers such as  
N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP) and N-succinimidyl 3-(2-pyridyldithiol)butyrate 
(SPDB) allow amide bond on one end and disulfide bond on the other end, which may be cleaved in 
reductive environment of some cancer cells. Besides, since maytansinoids and MMAE are synthetic 
analogs of their natural product counterparts, sulfhydryl or amine groups can be added during 
synthesis, making them adaptable to various conjugation chemistry methods. Therefore, the main Biomedicines 2014, 2 6 
 
 
conjugation sites on antibodies are cysteines (both native and mutated cysteines) and lysines. Although 
studies on conjugations through carbohydrates [50,51] and selenocysteines [52] have been reported, 
they have yet to reach clinical tests.  
Cysteine and lysine are two most common naturally occurring amino acids which are used to attach 
the drug through the linker to the antibody. IgGs have four pairs of interchain disulfide bonds, two 
between the heavy chains in the hinge region and one on each Fab between CH1 and CL domains 
(Figure 1A). Intrachain disulfide bonds are to be left intact because they are critical to maintain the 
basic IgG domain structure essential for antigen recognition, stability and effector functions. Only 
partial reduction of the interchain disulfide bonds at the hinges gives eight potential conjugation sites. 
During the conjugation step, molar ratio of free drug and antibody may be adjusted such that 
approximately four molecules of drugs are attached to each antibody [4,53]. Brentuximab vedotin is 
conjugated to maleimide-VC-PAB-MMAE on its cysteines [53] (Figure 1A). In the case of 
Brentuximab vedotin, addition of VC dipeptide provides a proteolytic site for the lysosomal protease 
cathepsin B to release the drug [54]. Proteolytic activity is abundant in late endosome/lysosomes, such 
design facilitates rapid release of drug for efficient cell killing.  
Figure 1. Structural elucidation of antibody drug conjugates (ADCs) using the IgG crystal 
structure (PDB code: 1HZH) with two-dimensional drawings of drug molecules with linker 
and spacers (not drawn to scale). (A) A model of brentuximab vedotin in which conjugation 
of cysteines via maleimidocaproyl-VC dipeptide-PAB-MMAE is shown. Residues in orange 
spheres represent the eight naturally occurring cysteines; (B) A model of trastuzumab 
emtansine in which the drug maytansinoid DM1 is linked to lysines via SMCC thioether. 
Residues in blue sticks represent the more than eighty naturally occurring lysines. 
 
The advantage of conjugation through cysteines is the relatively mild condition for reduction and 
conjugation. The procedure poses minimal risk to the stability of IgGs. The conjugation step is often Biomedicines 2014, 2 7 
 
 
efficient. There is an established method to monitor the intermediate product and final product   
ADCs [55]. However, the method gives a mixture of ADCs with 0 to 8 drugs per antibody. To 
overcome the heterogeneity, site specific conjugation through engineered cysteines, such as 
THIOMAB [56] has been explored to provide a more homogenous final ADCs with defined drug 
antibody ratio of 2, better stability and larger therapeutic window. It has been reported that site of 
conjugation also impacted on ADC stability. Site specific cysteines on heavy, light and Fc regions with 
various solvent accessibilities have different overall stability and therapeutic index [57].  
For conjugation through lysines, the primary amine on lysine side chain provides a convenient 
reactive group for conjugation chemistry. Overall, in an average IgG molecule, there are more than 
eighty lysine residues and almost a half of them having their side chains exposed to the surface of 
folded IgG (Figure 1B). More importantly, lysine is not a common residue in the CDR regions which 
minimizes possible interference of antigen recognition properties while lysine based conjugation of 
ADCs are used. However, the availability of large number of potential lysine conjugations sites 
compared to the small number of antibody to antibody ratio (DAR) could lead to a highly 
heterogeneous mixture. For example, the ADC huN901-DM1 involves about 20 different lysine 
residues in both light and heavy chains that are found in areas of structural flexibility and with large 
solvent accessibility [58]. In the recently approved trastuzumab emtansine (T-DM1), the lysine 
residues on the antibody trastuzumab are connected to a cytotoxic maytansine derivative DM1 through 
a stable thioether linker N-succinimidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate (SMCC) 
(Figure 1B). While the N-hydroxysuccinimide ester forms a stable amide bond with the primary amine 
of any of the available lysine residues of the antibody at pH 7–9, the maleimide moiety undergoes 
Michael addition reaction with sulfhydryl groups at pH 6.5–7.5 forming stable thioether bonds which 
are used to attach the drug to the antibody. The conjugation process leads to the formation of a mixture 
of ADCs with DARs ranging from 0–9, with an average value of 3.5 [59]. The DM1 binds directly to 
microtubules and inhibits their assembly thereby causing cell death [60]. Although there is no releasing 
trigger moiety in the T-DM1, following the internalization by the target cancer cells via antigen-mediated 
endocytosis it was delivered to lysosomes by the vesicular trafficking, and then degraded into the 
lysine derivatives, lysine-N
ε-SMCC-DM1 [61], which likely bind to the tubulin and cause cytotoxicity 
by the inhibition of microtubule polymerization. 
Lysine conjugation are also used in other ADCs including inotuzumab ozogamincin that is currently 
in Phase 3 clinical testing for non-Hodgkin lymphoma (NHL) in combination with rituximab [62]. The 
ADC, inotuzumab ozogamincin has anti-CD22 antibody with 78 lysine residues available for 
conjugating to cytotoxic drug N-acetyl-γ-calicheamicin via acetyl butyrate hydrazine. The linker drug 
molecule preferentially attaches to lysines on the heavy chain. The same lysine conjugation as well as 
drug and linker moieties is used in the other ADC, gemtuzumab ozogamicin (Mylotarg) targeting 
CD33 which was approved in 2000 by FDA but voluntarily withdrawn in 2010. Both inotuzumab 
ozogamincin and gemtuzumab ozogamicin use a hydrazone linker connecting through the cytotoxic 
drug N-acetyl-γ-calicheamicin to the antibody, in which the hydrazone is first cleaved in the acidic 
intracellular environment followed by the reduction of disulfide bridge in the calicheamicin [63]. 
Overall, in the case of conjugation through lysine residue, the cytotoxic drug attachment to the 
antibody typically occurs at a relatively very few ε-amino groups of any of the ~80 lysine residues 
present in the antibody, because the preferential surface accessibility for the lysine side chains to Biomedicines 2014, 2 8 
 
 
chemical modification is limited. ADCs with the DAR value of more than certain value, for example 
more than five, are usually hydrophobic and can lead to solubility problem. Currently, the widely used 
chemical method for lysine conjugation involves the formation of a stable amide bond using activated 
ester of the drug molecules, and several methods for the preparation of ADCs through lysine 
conjugation were described [64].  
Therefore, both conjugation methods described above are useful and resulting in several ADCs, two 
of which were approved by the FDA and others are in late clinical development. However, the 
complexity of ADCs often leads to heterogeneous distribution of drug molecules conjugated to 
antibodies and unfavorable physicochemical properties including increased aggregation with higher 
number of DARs, poor aqueous solubility and low stability in circulation.  
5. Conclusions  
The two recently FDA approved ADCs and growing number of ADCs in the pipeline present 
promising opportunities in treating various cancers and other diseases. The main optimization 
parameters in the development of successful ADCs include selection of targets, specificity of mAbs, 
drug potency, linker stability, and conjugation methods (inter-chain or engineered cysteines, lysines, 
and Fc glycans). Receptors or cell surface proteins that are overexpressed on tumor cells as compared 
to normal tissue are good candidate targets. In addition to the usual requirement of therapeutic mAbs, 
the mAbs used in ADCs must have sufficient aggregation-resistance to withstand the hydrophobicity 
brought on by adding the drug molecules, and maintain stability and affinity for targets upon 
conjugation. The selection of antibody isotype, the ability for internalization and tumor penetration are 
also important. The cytotoxic drugs used in ADCs should be rapidly released in active forms in the 
intracellular environment. The number of drug molecules in ADCs depend on the method of 
conjugation, desired potency and linkers [65]. The linkers used in ADCs are a key component, which 
influences the stability of ADCs and release of drug molecules [66]. Therefore, the choice of linkers 
used in ADCs profoundly affects the thermal stability, half life, toxicity and the overall efficacy of the 
ADCs [67]. In order to render better control on the drug/linker conjugation sites on antibodies and the 
desired DAR, better linker and conjugation methods are needed, as well as rational approaches for 
improving physicochemical properties and therapeutic index of ADCs.  
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